Vermillion Corporation

Leland Stanford Junior University

The Johns Hopkins University

Aspira Women's Health Inc.

Fujun Zhang

Eric Thomas Fung

John P Cooke

Zhen Zhang

Daniel W Chan

Zheng Wang

Tai-Tung Yip

Xiao-Ying Meng

Andrew Wilson

The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

Biomarkers for ovarian cancer CTAP3-related proteins

Biomarker for ovarian cancer CTAP3-related proteins

This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

Biomarkers for peripheral artery disease

The invention provides biomarkers including &#x3b2;-2-microglobulin, Cystatin C, hsCRP and glucose as well as methods for using the biomarkers for diagnosing and/or assessing the risk of peripheral artery disease in a subject. In some embodiments, the subject being tested may be suffering from or at risk of other circulatory diseases, including coronary artery disease. Hemoglobin A1c or other proxies for measuring glucose levels may be substituted for or measured in addition to glucose in the context of the present invention.

Panel of biomarkers for peripheral arterial disease

Growing community of inventors

Fremont, CA, United States of America

Fujun Zhang